J&J’s Antipsychotic Invega Gets Long-Term Treatment Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Schizophrenia therapy is seen as a follow-on to Risperdal.
You may also be interested in...
Abilify, Risperdal Compete To Become First Antipsychotic Approved For Pediatric Schizophrenia
User fee date could be as early as June 21 for Johnson and Johnson subsidiary Janssen’s Risperdal, firm tells “The Pink Sheet” DAILY.
Abilify, Risperdal Compete To Become First Antipsychotic Approved For Pediatric Schizophrenia
User fee date could be as early as June 21 for Johnson and Johnson subsidiary Janssen’s Risperdal, firm tells “The Pink Sheet” DAILY.
AstraZeneca’s Seroquel XR Gets FDA Nod For Once-Daily Treatment Of Schizophrenia
AstraZeneca plans to have the extended-release tablets on the market by late July, firm tells “The Pink Sheet” DAILY.